Alpidem analogues containing a GABA or glycine moiety as new anticonvulsant agents

European Journal of Pharmaceutical Sciences

Volumn 18, Issue 3-4, 2003, Pages 231-240

  Trapani, Giuseppe ^a   Latrofa, Andrea ^a   Franco, Massimo ^a   Carrieri, Antonio ^a   Cellamare, Saverio ^b   Serra, Mariangela ^c   Sanna, Enrico ^c   Biggio, Giovanni ^c   Liso, Gaetano ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Blood brain barrier; Imidazopyridine compounds; Inhibitory neurotransmitters

Indexed keywords

ASSAYS; DERIVATIVES; SYNTHESIS (CHEMICAL);

ANTICONVULSANT AGENTS;

DRUG PRODUCTS;

4 AMINOBUTYRIC ACID DERIVATIVE; 4 AMINOBUTYRIC ACID RECEPTOR; ACETAMIDE DERIVATIVE; ALPIDEM; ANTICONVULSIVE AGENT; BENZODIAZEPINE RECEPTOR; FLUNITRAZEPAM; GLYCINE DERIVATIVE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PENTETRAZOLE; PYRIDINE DERIVATIVE; RECOMBINANT RECEPTOR; STRYCHNINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CONVULSION; DRUG BINDING; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; LATENT PERIOD; NEUROPROTECTION; NONHUMAN; OOCYTE; PRIORITY JOURNAL; RAT; SEIZURE; XENOPUS LAEVIS;

EID: 0037345480     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(03)00002-2     Document Type: Article

References (24)

1. Aprison M.H. Ottersen O.P., Storm-Mathisen J. The Discovery of the Neurotransmitter Role of Glycine in Glycine Neurotransmission. 1990;1-23 Wiley, New York.
2. Benavides J., Peny B., Ruano D., Vitorica J., Scatton B. Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem. Brain Res. 604:1993;240-250.
3. Bialer M. Pharmacokinetic consideration in the design of better and safer new antiepileptic drugs. J. Controlled Rel. 62:1999;187-192.
4. Bodor N., Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev. 36:1999;229-254.
5. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 88:1999;815-821.
6. Durand A., Thenot J.P., Bianchetti G., Morselli P.L. Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab. Rev. 24:1992;239-266.
7. Geurts M., Poupaert J.H., Scriba G.K.E., Lambert D.M. N-(Benzyloxycarbonyl)glycine esters and amides as new anticonvulsants. J. Med. Chem. 41:1998;24-30.
8. Giesen-Crouse E. Giesen-Crouse E. Peripheral Benzodiazepine Receptors. 1993;Academic Press, London.
9. Krogsgaard-Larsen P. Amino acid receptors. Hansch C., Sammes P.G., Taylor B.J. Comprehensive Medicinal Chemistry. 1990;493-531 Pergamon Press, Oxford. Chapter 12.7.
10. Krogsgaard-Larsen P. GABA synaptic mechanisms: Stereochemical and conformational requirements. Med. Res. Rev. 8:1988;27-56.
11. Le Fur G., Perrier M.L., Vaucher N., Imbant F., Flamier A., Uzan A., Renault C., Dubroeucq M.C., Gueremy C. Peripheral binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci. 32:1983;1839-1847.
12. Lloyd K.G., Morselli P.L. Biochemistry, anatomy, and pharmacology of GABA neurons. Melzer H.Y. Psychopharmacology: The Third Generation of Progress. 1983;183-201 Raven Press, New York.
13. Lowry O.M., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
14. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 232:1986;1004-1007.
15. McNamara J.O., Bonhaus D.W., Shin C. Schwartzkroin P.A. Epilepsy: Models, Mechanisms and Concepts. 1993;27-47 University Press, Cambridge.
16. Norinder U., Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv. Drug Deliv. Rev. 54:2002;291-313.
17. Pfeiffer F., Betz H. Solubilization of the glycine receptor from rat spinal cord. Brain Res. 226:1981;273-279.
18. Stenberg P., Luthman K., Ellens H., Lee C.P., Smith P.L., Lago A., Elliott J.D., Artursson P. Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity. Pharm. Res. 16:1999;1520-1526.
19. Toth E., Lajhta A., Sarhan S., Seiler N. Anticonvulsant effects of some inhibitory neurotransmitter amino acids. Neurochem. Res. 8:1983;291-302.
20. Trapani G., Franco M., Ricciardi L., Latrofa A., Genchi G., Sanna E., Tuveri F., Cagetti E., Biggio G., Liso G. Synthesis and binding affinity of 2-phenylimidazo[1,2-a]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral type. J. Med. Chem. 40:1997;3109-3118.
21. Trapani G., Franco M., Latrofa A., Ricciardi L., Carotti A., Serra M., Sanna E., Biggio G., Liso G. Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors. Synthesis, binding affinity, and in vivo studies. J. Med. Chem. 42:1999;3934-3941.
22. Usifoh C.O., Lambert D.M., Wouters J., Scriba G.K. Synthesis and anticonvulsant activity of N,N-phthaloyl derivatives of central nervous system inhibitory amino acids. Arch. Pharm. (Weinheim). 334:2001;323-331.
23. Van de Waterbeemd H., Camenish G., Folkers G., Chretien J.R., Raevsky O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Targeting. 6:1998;151-165.
24. Wermuth C.G., Gaignault J.C., Marchandeau C. Designing prodrugs and bioprecursors I: carrier prodrugs. Wermuth C. The Practice of Medicinal Chemistry. 1996;672-696 Academic Press, New York.